Read the offer, as well as the label
The FDA, the Food and Drug Administration, looks at what a product is intended to do, including claims made on its sales page.
In warning letters reviewed September 26, 2026, the FDA pointed to sellers’ treatment claims and the mixing water sold with their products. The water gave buyers a way to prepare the products for injection. The FDA treated this as evidence that the products were meant for people, despite their research labels.
Those letters concern particular businesses and state the agency’s allegations. They are not court judgments.
A laboratory label does not answer who will examine you, what is in the finished product, or who will handle a problem. Ask those care questions directly.
A product name still needs its own check
Neither BPC-157 nor retatrutide has a US-approved product in FDA records checked September 26, 2026.
The FDA also states, as of that date, that retatrutide and cagrilintide have no lawful route for compounding under federal law.
Ask about each named ingredient separately.
- What exact product is being offered?
- Who would assess whether it fits my care?
- Can the clinician explain its current status from an official source?